ZA200101972B - In-vitro method for detecting and diagnosing acute coronary syndromes. - Google Patents
In-vitro method for detecting and diagnosing acute coronary syndromes. Download PDFInfo
- Publication number
- ZA200101972B ZA200101972B ZA200101972A ZA200101972A ZA200101972B ZA 200101972 B ZA200101972 B ZA 200101972B ZA 200101972 A ZA200101972 A ZA 200101972A ZA 200101972 A ZA200101972 A ZA 200101972A ZA 200101972 B ZA200101972 B ZA 200101972B
- Authority
- ZA
- South Africa
- Prior art keywords
- choline
- group
- enyl
- alk
- cctd
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 146
- 208000004476 Acute Coronary Syndrome Diseases 0.000 title claims description 22
- 238000000338 in vitro Methods 0.000 title claims description 21
- 229960001231 choline Drugs 0.000 claims description 69
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 67
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 60
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 57
- 239000007795 chemical reaction product Substances 0.000 claims description 46
- 239000000126 substance Substances 0.000 claims description 34
- -1 plasmalogens Chemical compound 0.000 claims description 27
- HTZINLFNXLXRBC-CQLBIITFSA-N 1-(1Z-hexadecenyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC\C=C/OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C HTZINLFNXLXRBC-CQLBIITFSA-N 0.000 claims description 25
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims description 25
- 229950004354 phosphorylcholine Drugs 0.000 claims description 25
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 25
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical class OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 claims description 24
- 210000001124 body fluid Anatomy 0.000 claims description 23
- 239000010839 body fluid Substances 0.000 claims description 23
- 230000001900 immune effect Effects 0.000 claims description 21
- 210000004369 blood Anatomy 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 20
- 238000003745 diagnosis Methods 0.000 claims description 17
- 150000002314 glycerols Chemical class 0.000 claims description 15
- 238000004458 analytical method Methods 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 14
- 238000011156 evaluation Methods 0.000 claims description 13
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 12
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 9
- 238000005481 NMR spectroscopy Methods 0.000 claims description 8
- 210000002700 urine Anatomy 0.000 claims description 7
- 239000006046 creatine Substances 0.000 claims description 6
- 229960003624 creatine Drugs 0.000 claims description 6
- 238000003909 pattern recognition Methods 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 101100313185 Homo sapiens CCT4 gene Proteins 0.000 description 138
- 102100029958 T-complex protein 1 subunit delta Human genes 0.000 description 138
- 230000001154 acute effect Effects 0.000 description 37
- 239000000523 sample Substances 0.000 description 34
- 206010061216 Infarction Diseases 0.000 description 16
- 230000007574 infarction Effects 0.000 description 16
- 239000012071 phase Substances 0.000 description 16
- 150000003904 phospholipids Chemical class 0.000 description 16
- 102000015439 Phospholipases Human genes 0.000 description 15
- 108010064785 Phospholipases Proteins 0.000 description 15
- 206010002383 Angina Pectoris Diseases 0.000 description 13
- 238000005259 measurement Methods 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 229940112042 peripherally acting choline derivative muscle relaxants Drugs 0.000 description 9
- 150000003248 quinolines Chemical class 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 235000008979 vitamin B4 Nutrition 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000013399 early diagnosis Methods 0.000 description 7
- 102000011420 Phospholipase D Human genes 0.000 description 6
- 108090000553 Phospholipase D Proteins 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000011325 microbead Substances 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 6
- 238000004611 spectroscopical analysis Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 102000004903 Troponin Human genes 0.000 description 5
- 108090001027 Troponin Proteins 0.000 description 5
- 102000014384 Type C Phospholipases Human genes 0.000 description 5
- 108010079194 Type C Phospholipases Proteins 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 208000031225 myocardial ischemia Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 4
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 4
- 102000004420 Creatine Kinase Human genes 0.000 description 4
- 108010042126 Creatine kinase Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 238000002306 biochemical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000011720 Lysophospholipase Human genes 0.000 description 3
- 108020002496 Lysophospholipase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000002586 coronary angiography Methods 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 150000008105 phosphatidylcholines Chemical class 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 2
- 102000036675 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 2
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 2
- 108010065729 Troponin I Proteins 0.000 description 2
- 102000004987 Troponin T Human genes 0.000 description 2
- 108090001108 Troponin T Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000011152 fibreglass Substances 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007576 microinfarct Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 238000004305 normal phase HPLC Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035778 pathophysiological process Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- HRQDDZWMEGEOOO-UHFFFAOYSA-N 2-trimethylsilylpropanoic acid Chemical compound OC(=O)C(C)[Si](C)(C)C HRQDDZWMEGEOOO-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 241000973887 Takayama Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010022198 alkylglycerophosphoethanolamine phosphodiesterase Proteins 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003796 diagnosis of exclusion Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000011141 high resolution liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 238000012594 liquid chromatography nuclear magnetic resonance Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- 108010077055 methylated bovine serum albumin Proteins 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010995 multi-dimensional NMR spectroscopy Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000000079 presaturation Methods 0.000 description 1
- 230000001536 pro-arrhythmogenic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000009774 resonance method Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nuclear Medicine (AREA)
- Electrotherapy Devices (AREA)
- Excavating Of Shafts Or Tunnels (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19836617A DE19836617C2 (de) | 1998-08-12 | 1998-08-12 | In vitro Verfahren zur Erkennung und Diagnostik akuter koronarer Syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200101972B true ZA200101972B (en) | 2003-07-02 |
Family
ID=7877351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200101972A ZA200101972B (en) | 1998-08-12 | 2001-03-09 | In-vitro method for detecting and diagnosing acute coronary syndromes. |
Country Status (16)
Country | Link |
---|---|
US (1) | US6830932B1 (cs) |
EP (1) | EP1104547B1 (cs) |
JP (1) | JP2002522791A (cs) |
AT (1) | ATE242488T1 (cs) |
AU (1) | AU761226B2 (cs) |
CA (1) | CA2339023C (cs) |
CZ (1) | CZ299988B6 (cs) |
DE (2) | DE19836617C2 (cs) |
DK (1) | DK1104547T3 (cs) |
ES (1) | ES2201764T3 (cs) |
HU (1) | HUP0102984A3 (cs) |
IL (2) | IL141152A0 (cs) |
NZ (1) | NZ509406A (cs) |
PT (1) | PT1104547E (cs) |
WO (1) | WO2000010014A1 (cs) |
ZA (1) | ZA200101972B (cs) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE397938T1 (de) * | 2000-05-19 | 2008-07-15 | Amylin Pharmaceuticals Inc | Behandlung des akuten koronaren syndroms mit glp- 1 |
US7262017B2 (en) * | 2001-09-14 | 2007-08-28 | Torrey Pines Institute For Molecular Studies | Diagnostic markers for ischemia |
US20080020472A1 (en) * | 2005-11-22 | 2008-01-24 | Frantz Biomarkers, Llc | Method for detecting an inflammatory disease or cancer |
US7491504B2 (en) * | 2005-11-22 | 2009-02-17 | Frantz Biomarkers, Llc | Method for detecting ovarian cancer |
WO2007092331A2 (en) * | 2006-02-02 | 2007-08-16 | Esa Biosciences, Inc. | Detection methods and devices |
WO2008027098A2 (en) * | 2006-05-31 | 2008-03-06 | Esa Biosciences, Inc. | Biosensor for measurement of species in a body fluid |
CN101675337A (zh) * | 2007-04-13 | 2010-03-17 | 菲诺梅诺米发现公司 | 用于缩醛磷脂缺乏介导的衰老疾病的诊断和危险评估的方法 |
US7811749B2 (en) * | 2008-04-21 | 2010-10-12 | Abbott Laboratories | Measuring free choline to determine suitability of erythrocytes for transfusion |
JP5662060B2 (ja) * | 2010-06-04 | 2015-01-28 | 学校法人帝京大学 | 検出方法 |
JP2012024014A (ja) * | 2010-07-23 | 2012-02-09 | Asahi Kasei Pharma Kk | 全血コリンの測定方法 |
CN102998274A (zh) * | 2012-11-30 | 2013-03-27 | 华南理工大学 | 一种快速测定制浆黑液中总硫含量的方法 |
CN111505131B (zh) * | 2020-01-02 | 2023-03-31 | 东莞东华医院有限公司 | 基于血清代谢组学改变建立的预测冠心病斑块不稳定性临床模型 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1598739C3 (de) | 1965-01-26 | 1973-10-11 | Merck Patent Gmbh, 6100 Darmstadt | Mittel zur Bestimmung der Chohnesteraseaktivitat im Serum |
AU5959990A (en) * | 1989-08-14 | 1991-04-03 | Queen's University At Kingston | Method for stimulating fibrinolytic effect |
US5604105B1 (en) * | 1990-10-12 | 1999-08-24 | Spectral Diagnostics Inc | Method and device for diagnosingand distinguishing chest pain in early onset thereof |
-
1998
- 1998-08-12 DE DE19836617A patent/DE19836617C2/de not_active Expired - Fee Related
-
1999
- 1999-08-11 IL IL14115299A patent/IL141152A0/xx active IP Right Grant
- 1999-08-11 PT PT99942859T patent/PT1104547E/pt unknown
- 1999-08-11 ES ES99942859T patent/ES2201764T3/es not_active Expired - Lifetime
- 1999-08-11 US US09/762,691 patent/US6830932B1/en not_active Expired - Fee Related
- 1999-08-11 NZ NZ509406A patent/NZ509406A/en not_active IP Right Cessation
- 1999-08-11 AT AT99942859T patent/ATE242488T1/de not_active IP Right Cessation
- 1999-08-11 EP EP99942859A patent/EP1104547B1/de not_active Expired - Lifetime
- 1999-08-11 HU HU0102984A patent/HUP0102984A3/hu unknown
- 1999-08-11 DE DE59905860T patent/DE59905860D1/de not_active Expired - Lifetime
- 1999-08-11 CZ CZ20010281A patent/CZ299988B6/cs not_active IP Right Cessation
- 1999-08-11 WO PCT/EP1999/005911 patent/WO2000010014A1/de active IP Right Grant
- 1999-08-11 JP JP2000565402A patent/JP2002522791A/ja active Pending
- 1999-08-11 CA CA002339023A patent/CA2339023C/en not_active Expired - Fee Related
- 1999-08-11 AU AU56219/99A patent/AU761226B2/en not_active Ceased
- 1999-08-11 DK DK99942859T patent/DK1104547T3/da active
-
2001
- 2001-01-29 IL IL141152A patent/IL141152A/en not_active IP Right Cessation
- 2001-03-09 ZA ZA200101972A patent/ZA200101972B/en unknown
Also Published As
Publication number | Publication date |
---|---|
PT1104547E (pt) | 2003-10-31 |
CA2339023C (en) | 2009-11-17 |
CZ299988B6 (cs) | 2009-01-14 |
NZ509406A (en) | 2003-05-30 |
DE19836617A1 (de) | 2000-03-16 |
IL141152A (en) | 2006-08-01 |
US6830932B1 (en) | 2004-12-14 |
HUP0102984A2 (hu) | 2001-11-28 |
AU761226B2 (en) | 2003-05-29 |
DK1104547T3 (da) | 2003-09-29 |
ES2201764T3 (es) | 2004-03-16 |
AU5621999A (en) | 2000-03-06 |
WO2000010014A1 (de) | 2000-02-24 |
EP1104547B1 (de) | 2003-06-04 |
CZ2001281A3 (cs) | 2001-07-11 |
DE19836617C2 (de) | 2001-02-08 |
IL141152A0 (en) | 2002-02-10 |
EP1104547A1 (de) | 2001-06-06 |
ATE242488T1 (de) | 2003-06-15 |
CA2339023A1 (en) | 2000-02-24 |
DE59905860D1 (de) | 2003-07-10 |
HUP0102984A3 (en) | 2005-06-28 |
JP2002522791A (ja) | 2002-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Beaumont et al. | Classification of hyperlipidaemias and hyperlipoproteinaemias. | |
Petroff et al. | High‐resolution proton magnetic resonance analysis of human cerebrospinal fluid | |
AU761226B2 (en) | In-vitro method for detecting and diagnosing acute coronary syndromes | |
US20050142613A1 (en) | Test for the rapid evaluation of ischemic states and kits | |
AU2012288742A1 (en) | Means and methods for diagnosing and monitoring heart failure in a subject | |
WO2007110357A2 (en) | Means and method for diagnosing diabetes | |
WO2001014881A1 (en) | Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-ms immune response | |
US20100081160A1 (en) | Method for Diagnosing Multiple Sclerosis | |
US7642338B2 (en) | Tacrolimus standard and methods of using same | |
Chan et al. | Time-resolved immunofluorometric assay of alpha-fetoprotein in serum and amniotic fluid, with a novel detection system. | |
CN117074700A (zh) | 用于诊断冠状动脉狭窄程度的代谢标志物及其应用 | |
US20130011870A1 (en) | Method For Assaying Diseases Characterized By Dyslipidemia | |
CN115327129A (zh) | 一种血浆分子标志物犬尿氨酸在早期心力衰竭检测中的应用 | |
AU2012264688A2 (en) | Methods for diagnosing multiple sclerosis | |
US7297544B2 (en) | Tests for the rapid evaluation of ischemic states and kits | |
Lin et al. | Positive interference from contrast media in cardiac troponin I immunoassays | |
Sidki et al. | Direct determination of phenobarbital in serum or plasma by polarization fluoroimmunoassay | |
US4764601A (en) | Composition for assaying cardiac glycosides from serum or plasma | |
WO2004054431A2 (en) | Tests for the rapid evaluation of ischemic states and kits | |
US20030215359A1 (en) | Tests for the rapid evaluation of ischemic states and kits | |
CN113504324A (zh) | 胆汁淤积症预后生物标记物检测试剂盒 | |
Nicholson | High resolution nuclear magnetic resonance spectroscopy in clinical chemistry and disease diagnosis | |
JPH07280811A (ja) | 3α,11β−ジヒドロキシ−4−アンドロステン−17−オンの測定法 | |
Moldoveanu et al. | Postmortem Specificity of Troponin for Acute Myocardial Infarction Diagnosis Through Qualitative Dosing from Pericardial Fluid | |
Carbury | The establishment of a therapeutic monitoring service for digoxin |